The ROE as of September 2024 (TTM) for MannKind Corporation (MNKD) is -4.92%

According to MannKind Corporation’s latest financial reports and current stock price. The company's current ROE is -4.92%. This represents a change of 295.20% compared to the average of -1.25% of the last 4 quarters.

MannKind Corporation (MNKD) Historical ROE (quarterly & annually)

How has MNKD ROE performed in the past?

The mean historical ROE of MannKind Corporation over the last ten years is 56.65%. The current -4.92% ROE has changed -108.69% with respect to the historical average. Over the past ten years (40 quarters), MNKD's ROE was at its highest in in the September 2014 quarter at 89.78%. The ROE was at its lowest in in the September 2016 quarter at -53.01%.

MannKind Corporation (MNKD) ROE by Quarter and Year

Discovering the peaks and valleys of MannKind Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MannKind Corporation (MNKD) Average ROE

How has MNKD ROE performed in the past?

The current ROE of MannKind Corporation (MNKD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MannKind Corporation (MNKD) ROE vs. Peers

How is MNKD’s ROE compared to its peers?

MannKind Corporation’s ROE is less than BioMarin Pharmaceutical Inc. (5.08%), greater than Vaxcyte, Inc. (-30.07%), greater than Liquidia Corporation (-183.58%), greater than Legend Biotech Corporation (-23.20%), less than Bio-Techne Corporation (8.36%), less than United Therapeutics Corporation (18.82%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Kiniksa Pharmaceuticals, Ltd. (-5.10%), greater than Verastem, Inc. (-133.02%), greater than ImmunoGen, Inc. (-21.97%), greater than Immutep Limited (-42.11%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Elevation Oncology, Inc. (-57.97%), less than Acer Therapeutics Inc. (0%), less than NRx Pharmaceuticals, Inc. (196.73%), less than Pasithea Therapeutics Corp. (193.11%), greater than SAB Biotherapeutics, Inc. (-74.63%), greater than MiNK Therapeutics, Inc. (-94.04%), less than Affimed N.V. (99.78%), greater than Adaptimmune Therapeutics plc (-155.57%), greater than Sangamo Therapeutics, Inc. (-117.47%), greater than null (-334.92%),

Build a custom stock screener for MannKind Corporation (MNKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MannKind Corporation (MNKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.